NVO · Novo Nordisk ADR
United States · RS rating 46 · As of 2026-11-03
| Price | 40.19 USD |
|---|---|
| 1-day change | -0.6% |
| RS rating (overall / 1M / 3M / 12M) | 46 / 76 / 46 / 39 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 29 / 12 / 37 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | +34.2% |
| Sales growth Q/Q | +5.6% |
| Distance from 52-week high | +37.2% |
| Market cap (USD) | $170.8B |